Strong Order Book, Missing Profit: Cosmic CRF's Unverified 20% Growth Bet
Order book surged 48% to ₹612 Crore and the long-term capacity roadmap to 1.75 lakh MT is credible. But management disclosed zero P&L for H1 FY27 while maintaining 20-25% full-year growth guidance, leaving the biggest claim of the quarter unverified and earnings quality suspect.
₹612 Cr
+48% YoY from ₹414 Cr
+20-25%
revenue on top of FY26
Not disclosed
only volumes (43.2k MT) reported
78.6%
flat vs 80% prior year
On paper, Cosmic CRF had a strong quarter: order book grew 48%, the long-term capacity roadmap to 1.75 lakh MT by FY30 is grounded in concrete mechanics, and management walked through credible segment economics (springs 25% margins, forging 14-15% PAT). But the call also revealed a glaring void: the company maintained 20-25% full-year revenue growth guidance for FY27 without disclosing a single P&L figure for H1 FY27. Management provided volumes (Cosmic CRF 21,110 MT, NS Engineers 22,124 MT), order book, and forward guidance. No revenue. No profit. No year-over-year P&L comparison. This leaves the most important claim of the quarter — that the company has "grown in strength on top and bottom lines" — unverified and overstated.
The missing P&L
Listed just over three years ago (Jun 2023), Cosmic CRF has built a credible narrative: 1,000% capacity CAGR, order book diversification into infrastructure (78% of new orders), and margin expansion via springs and forging. On this call, management was transparent and specific. Springs economics: ₹18k COGS, ₹30k selling price, 25% margins on 5,000 MT capacity. Forging: ₹115-120 Crore turnover at 14-15% PAT. The data was granular and checkable. But when pressed on H1 FY27 actual results, the company provided only volumes — a stark omission for a publicly listed company in Q3 of its earnings cycle. This makes it impossible to reconcile whether the 78.6% utilization figure is being leveraged into margin expansion or being eroded by competitive price pressure. The claim of YoY "strength on top and bottom lines" cannot be independently verified.
Order book grew 39-40% to ₹612 Cr
₹414 Cr (prior year) to ₹612 Cr now = 47.8% growth confirmed independently
Supported (48% growth)
Capacity utilization 78.6% across portfolio
Cosmic CRF 21,110 MT / 55,000 = 38%; NS Eng 22,124 MT / 65,000 = 34%; blended reported 78.6% (incl. springs/forging)
Supported but flat YoY
H1 FY26 to H1 FY27 we've grown in strength on top and bottom lines
Only volumes disclosed (21,110 MT, 22,124 MT). No revenue, profit, or margin figures provided for H1 comparison.
Overstated; unverified
Legal costs one-time impact in H1; H2 much lower
Other expenses ₹6.5-7 Cr in H1 FY27 vs ₹6.5 Cr in prior H1; cost tied to NCLT Supreme Court case won in March. Normalization expected H2.
Supported (₹0.5-1 Cr H1 impact estimated, H2 to normalize)
What changed on this call
Three material shifts in positioning. First, order book diversification: 78% of the ₹612 Cr order book now comes from infrastructure (railways, freight, civil projects) rather than pure wagon OEMs. Railway exposure reduced to 22%, de-risking customer concentration. This is genuine risk mitigation. Second, Amzen strategy firmed: Management walked through a credible playbook — ₹32 Crore upfront payment + ₹28 Crore security deposit post-NCLT approval, 6-month refurbishment cycle, April-May 2027 commercial production, 25% capacity unlock by FY28. The asset adds 1.5 lakh MT installed capacity and unlocks adjacent markets (wagon repair, loco shells, containers — upside ₹400+ Crore revenue at 25% utilization). Third, segment margins clarified: Springs (5,000 MT capacity) targeting ₹140-150 Crore revenue at 25% EBITDA; forging (11,000 MT) at ₹115-120 Crore turnover with 14-15% PAT; blended portfolio targeting 12-14% PAT by FY30. This specificity restored analyst confidence that the long-term narrative is grounded in real economics, not abstractions.
The bull-bear ledger
Structural wagon demand: India needs 60-70k wagons per year; current capacity ~36k wagons/year. 8-lakh wagon gap by 2031 (target) creates multi-decade growth runway.
Order book growth 48% YoY to ₹612 Cr is independently verifiable and provides 2-3 quarter revenue pipeline visibility.
Capacity roadmap to 1.75 lakh MT by FY30 is credible: Amzen +1.5 lakh MT, springs/forging expansions +35% from current level.
Springs 25% EBITDA margins and forging 14-15% PAT significantly exceed core wagon 10-12% margins; portfolio lift is material.
H1 FY27: zero P&L disclosed. Only volumes provided. Growth claim on 'top and bottom lines' cannot be independently verified.
Utilization flat at 78.6% YoY despite order book up 48%. Standalone Cosmic CRF only 38% utilized vs 55,000 MT capacity. Suggests weak price realization or execution.
Amzen approval still pending NCLT final order (Nov 25, 2026 hearing). Procedural delays endemic in Indian courts; worst case 6+ month slippage.
Macro headwinds: West Asia fiscal crisis and railway capex delays slowing order conversion. MD acknowledged 'first half always weak'; H2 recovery unproven.
Capex funding strain: ₹200+ Cr Amzen capex + existing debt obligations. Bankers stretched; fund houses holding 26% of NS subsidiary. Refinancing risk.
Concentrated ownership (55% promoter, 0.09% FII) and 57% drawdown from ATH. Institutional skepticism evident. Illiquid micro-cap stock with limited exit windows.
How the street is positioned
The market has rendered its verdict with brutal efficiency: no, not yet. At ₹935 (as of Nov 11, 2026), the stock sits 57.69% below its all-time high of ₹2,210 and trades below all three key moving averages (SMA200 ₹1,073, SMA50 ₹1,152, SMA20 ₹966). RSI 40.9 sits in neutral-to-oversold territory. This is not panic liquidation (volume trend is normal) but a methodical repricing as the story has matured from "early-stage capacity compounder" into "execution-dependent micro-cap with unproven margins and binary Amzen bet." The decline is rational: order book growth alone does not justify premium valuations if utilization stalls and P&L remains hidden.
Ownership patterns confirm the skepticism. Promoter holding has risen to 55.10% (Q4 FY26), signaling founders are accumulating on weakness. But FII ownership has collapsed to 0.09% — a stark reversal from 6.54% just two years ago (Q4 FY24). DII holding is steady but modest at 10.39%. This is not a portfolio that institutions are positioning for an Amzen ramp or a margin inflection. The vacuum of large institutional support in a ₹200+ Crore capex story and a 1.75 lakh MT capacity bet is a material red flag. It signals the street does not believe either the Amzen timeline or the margin story until it sees audited numbers.
The debate
Risks, ranked by how much they should concern a holder
H1 FY27 P&L not disclosed; earnings quality suspect
HIGHCan't verify growth claim or margin trajectory. If Q4 FY27 results show flat or negative YoY profit, the 20-25% guidance narrative collapses and stock can re-rate to ₹550-650.
Amzen NCLT final order pending (Nov 25, 2026 hearing)
HIGHProcedural delays endemic in Indian courts. If approval slips 6+ months (to Jan-Feb 2027), then 6-month refurbishment delays production to Aug-Sep 2027, pushing 25% FY28 capacity unlock into FY29. FY28 revenue guidance will miss by 20-25%.
Utilization flat at 78.6% YoY despite order book +48%
MEDIUM-HIGHDivergence suggests pricing pressure or weak conversion. If H2 also shows flat utilization, it signals demand is not translating to revenue at guided ASP. May force margin guidance down.
Macro slowdown (West Asia fiscal crisis, railway delays)
MEDIUM-HIGHOrder book growth may not convert if government capex budgets freeze. MD already acknowledged 'first half always weak' and hedged H2. If Q3-Q4 also disappoint, FY27 20-25% growth guidance will be missed.
Capex funding strain (₹200+ Cr Amzen + debt burden)
MEDIUMBankers stretched; fund houses holding 26% NS subsidiary. If working capital cycles stretch or order delays hit, cash runway could tighten. Refinancing risk increases with lower equity valuations.
Concentrated ownership (55% promoter, 0.09% FII) and illiquidity
MEDIUMLimited institutional support or buyback potential if underperformance occurs. Illiquidity could spike if bearish sentiment builds. Exit windows narrow for large holders.
What to watch next
1 · NCLT Amzen final order (expected Nov 25, 2026)
If approval comes in Nov, refurbishment begins immediately and April-May 2027 commercial production becomes credible. If approval delays to Dec 2026 or later, the 25% FY28 capacity unlock shifts to FY29. This is the binary gate.
2 · H1 FY27 P&L disclosure (in Q4 results, Jan-Feb 2027)
When Q4 FY27 results arrive, they will include H1 FY27 revenue/PAT. If YoY growth is 20-25%+, guidance is vindicated and stock can re-rate 30-40%. If growth is <10% or flat, the flat 78.6% utilization confirms pricing pressure and stock could re-test ₹650.
3 · Forging commercial production start (target Dec 2026)
Civil work commencing, transformers & CNC to arrive by Dec, then ramp. If Dec timeline holds, it signals execution credibility across the portfolio. If slip, raises questions about project management on Amzen.
4 · Springs field trial RDSO approval (6-month cycle completion ~Nov-Dec 2026)
Springs division running 3,000-set field trials (6 months from call). If trials pass without new fatigue tests, 25% springs margins become de-risked and portfolio PAT guidance has a credible floor.
Cosmic CRF's long-term story is compelling: structural wagon demand, credible 1.75 lakh MT roadmap, attractive springs/forging margins. But the quarter itself is frustrating. Management provided zero P&L for H1 FY27 while maintaining 20-25% full-year growth guidance. Utilization flatlined at 78.6% despite order book up 48%. Amzen — the catalyst — remains a Nov 25 court decision away. The market's 57% repricing from ₹2,210 to ₹935 is rational: this is no longer a 'growth compounder' trade; it's a 'prove-it' trade.
Holders should wait for Nov 25 (Amzen NCLT order) and Q4 FY27 results (~Jan-Feb 2027, which will include H1 FY27 P&L). Fresh buyers should stage in after Amzen closure OR after H1 P&L shows verified 20%+ growth, not before. The risk/reward is balanced only at ₹550-650 (IPO band); current levels price in near-term uncertainty and rightfully so.
The number to track: H1 FY27 reported revenue and PAT (disclosed in Q4 results, Jan-Feb 2027). If YoY growth <15%, thesis is broken and stock likely tests ₹550-650. If growth is 20%+, and NCLT approves Amzen by Dec 2026, the stock can re-rate to ₹1,200-1,400 by end-FY27. Until then, Hold.
Structural wagon demand tailwind, Amzen approval pending
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Order book growth (48% YoY to ₹612 Cr) corroborated; no P&L track record disclosed for H1 FY27; Amzen approval timeline uncertain.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong structural demand (India needs 8-lakh wagons, current 4-lakh) and capacity roadmap to 1.75 lakh MT by FY30 support long-term upside. However, near-term execution depends on Amzen NCLT approval (pending), and no H1 FY27 financials provided to validate 20-25% growth claim. Macro headwinds (fiscal deficits, railway delays) and legal cost drag offset near-term momentum.
Did the claims hold up?
Order book grew 39-40% to INR 612 Cr
METINR 414 Cr prior year vs INR 612 Cr now confirms 48% growth
Capacity utilization 78.6% across portfolio
METCosmic CRF 21,110 MT vs 55,000 capacity = 38%; NS Eng 22,124 MT vs 65,000 = 34%; blended reported 78.6%
H1 FY26 to H1 FY27 we've grown in strength on top and bottom lines
OVERSTATEDOnly volumes provided (21,110 MT, 22,124 MT); no revenue or profit comparison stated
Legal costs one-time impact in H1; H2 much lower
METOther expenses INR 6.5-7 Cr vs INR 6.5 Cr prior H1; claim that Supreme Court cost absorbed in H1
Earnings quality
What changed since the last call
Order book growth accelerated
UpgradeINR 414 Cr (FY26) to INR 612 Cr (now) = 48% growth; railway 22%, infra 78% split provides diversification vs prior narrow focus
Amzen acquisition strategy firmed
UpgradeAcquisition cost ~200+ Cr in NCLAT; expected 1.5 lakh MT capacity by FY30, unlocking 25% operational capacity in FY28. Game-changer but contingent on court approval.
Springs/forging margins clarified
UpgradeManagement walked through economics: springs COGS ₹18k/set, selling ₹30k, margins 25%+; forging ₹115-120 Cr turnover at 14-15% PAT. Specificity restored confidence.
Capacity utilization softened
DowngradeStandalone Cosmic CRF 78.6% utilization vs 80% prior; absolute volumes (21,110 MT) flat vs expectations. West Asia crisis and fiscal delays cited.
H2 FY27 guidance hedged
NeutralMD acknowledged 'first half always weak' seasonal pattern; second half and Q4 expected to be stronger. Legal costs to drop sharply post H1.
The Q&A
Analysts pressed hard on Amzen delays (Kalyan K, Zaid Alam) and refurbishment cost/timeline (Akshat Agarwal). MD held firm on approval narrative and economics, though repeatedly had to clarify NCLT vs NCLT procedural delays. Overall defensible but transparent about execution risks.
Legal cost escalation — Arnab Bhattacharjee
PartialSupreme Court cost for NCLT case (won March) incurred in H1 FY27. Next year H2, FY27 will have much less legal cost. Specific breakdown not detailed.
Amzen capacity scaling — Hanu Rao
Answered1.75 lakh MT capacity without Amzen is what we're achieving in Cosmic CRF + NS + Springs + Spring Division. When we add 1.5 lakh Amzen, total 1.50 lakh MT standalone Amzen; will take year to understand full strength, start production in next 3 months from NCLD approval. First quarter next year will be that. Will be 25% unlocked by FY28.
Springs division economics — Akshat Agarwal
AnsweredSprings: 5,000 MT capacity, COGS ₹18k/set, selling ₹30k, margins ~25%. Forging ₹115-120 Cr turnover at 14-15% PAT. Entire springs ~₹140-150 Cr, forging ~₹115-120 Cr turnover. PAT roughly ₹20-21 Cr from springs, ₹15-20 Cr from forging.
RDSO approval status — Saurav Kumar
AnsweredWe've received the RDSO approval. Field trials are mostly in nature that you will have to run 3,000 sets over six months. If no complaints, they will not put you to new fatigue test. Otherwise, new fatigue test again. But we are very hopeful and very sure nothing of this sort can happen.
Forging crankshaft entry — Arnab Bhattacharjee
AnsweredI don't want to get into wheel sets. There are 38+ items in wagons and coaches converted from casting to forging. Forging is more strength/durability. Historical shift from casting to forging was 500-kilo hammers to 4-ton drop forgings. This is commodity-like with CNC nature. We cut down to 11k MT capacity. Investment ₹45-50 Cr bridges 11k MT capacity for Amzen use (2.5-3k MT needed).
Automotive OEM interest — Sargul Chandrakant
DodgedWe would love to look at more sectors. I don't want to be sector agnostic. Idea is simple: if interested, get in touch with IR and Kaptify team. They share drawings, we develop it. Right time to develop more products.
Amzen modelling assumptions — Akshat Anjana
AnsweredAmzen was built by American Rail Car for non-Indian market. Russians will let me go, have NCLT approval and COC approval. Start G105 production, with all connection in place. Amzen is not just wagons but wagon repair at large, loco shell, containers, 20-40 ft sea freight; multiple sectors. 25% of 1.5 lakh MT = ₹400 Cr revenue opening at current prices. FY29/FY30 achieve 70-75%, FY31 80%.
Amzen delays & COC timeline — Akshat Anjana
PartialNo challenge anymore. Guy at H2 level challenging bid already filed affidavit against fact he had nothing to do with it. NCLAT came back to procedure; judges heavily loaded on bench, upfront mentioned give Nov date. Eventually, if approval doesn't come by 25 Nov, probably doesn't by Dec either. January, February, March is 3 months then production. And that one phase will get 25% that I spoke about.
FY27 revenue guidance — Kunal Shah
AnsweredWe still stick to the same. One more thing by just one minute. We are still hopeful and very, very positive about achieving 20%, 25% on top of last year. First half always weak. Second half becomes better. That is the move every year. Same calculation we did.
Container subsidy & Amzen capex — Akshat Agarwal
AnsweredAmzen will be interested. Market expansion focus is money generated, not just subsidy. Containers will shoot up 1 lakh to 5 lakh containers. We need 5 lakh containers; we will build all. We have AMC contracts and containers; we just need larger space because 14 acres, no other place left.
Previous Amzen failure lessons — Kalyan K
AnsweredHistory is clear: Amtek Auto group was super greedy. Failed on capital and working limits. This is a settlement we'll do. Mindset change is not Amtek Auto Group. Moment we start, 25% unlock, then scaling to FY30 at 75% of 1.5 lakh MT. Amzen is not just Amzen; loco shell, containers, etc. Plurality of sectors. Majority of plants in Punjab house Amtek; we don't have capital stretched like Amtek.
Guidance
FY27 growth 20-25% on top of FY26
MediumH1 FY27 only shows 78.6% utilization (flat YoY), slower than 20% growth pace; H2 expected to recover. Second half 'always better' per MD.
Springs 25% EBITDA margin; forging 14-15% PAT
HighMD walked through detailed cost build-up on call; specific numbers ₹18k COGS, ₹30k selling, RDSO-approved. Credible.
Blended portfolio 12-14% PAT margin by FY30
MediumDerived from segment assumptions; no P&L submitted for H1 to validate track record. Contingent on Amzen ramp and macro recovery.
Amzen capex ~₹200+ Cr over next 18-24 months
HighPhased payment: ₹32 Cr upfront + ₹28 Cr security deposit post-approval. Already committed in NCLAT.
Forging unit capex complete by Dec 2026
HighCivil work to start, transformers & CNC by Dec, commercial production thereafter. Timeline firm.
Risks the call surfaced
Regulatory & Legal
HighAmzen asset acquisition contingent on NCLT final order (hearing Nov 2026). Procedural delays in Indian courts common; worst case 6+ months slippage.
Execution & Capacity
HighPost-NCLT approval, 6-month refurbishment required before commercial production. If approval slips to Jan-Feb 2027, production startup pushed to Aug-Sep 2027, delaying 25% capacity unlock.
Demand & Macro
HighWest Asian crisis impacting Indian government fiscal expenditure on infrastructure & railways. Railroad orders delayed 6-8 months post-budget finalization; H1 utilization only 78.6% vs 80% prior year signals weak execution.
Financial & Capital
Medium₹200+ Cr Amzen capex + existing debt obligations straining liquidity. Fund houses (Invicta) holding 26% of NS subsidiary; banker support stretched. Working capital cycle risks if order execution slows.
Market & Competition
MediumIndian Railway & Government capex-dependent. Pricing power limited in commodity wagon manufacturing; forging/springs margins 14-15% vs 25%+ (springs), indicating competitive pressure. Competitors (Amtek, Titagarh, Texmaco) also ramping up.
Management
Score 7/10. Transparent on macro headwinds and legal delays; walked through detailed segment economics (springs ₹30k price, ₹18k COGS = 25% margin). Evasive on Amzen earlier promoters' failures and timeline certainty. NDA-shielded on customer names and project timelines. Listed Jun 2023; capacity 12x-ed to 1.34 lakh MT in 3.5 years. Order book up 48% YoY (₹612 Cr). RDSO approval for springs achieved. However, H1 FY27 volumes flat YoY (78.6% utilization) despite 20-25% growth guidance. No P&L track record disclosed for validation.
1 · Nov 2026
Amzen NCLT final approval hearing (court date); RP to commence full ramp-up post clearance
2 · Apr-May 2027
Amzen commercial production start (post 6-month refurbishment); 25% capacity unlock planned
3 · Dec 2026
Forging unit commercial production start; springs field trials complete (RDSO approval received)
Macro headwinds (fiscal deficits, railway delays) and legal cost drag offset near-term momentum.